Skip to contentP
Petros Pharmaceuticals, Inc.
P
PTPIPetros Pharmaceuticals, Inc. Q2 2025 · 10-Q
Revenue—
Net Income$5.43M$5.43MN/M vs Q2 2024 EPS Diluted-$1.20-$1.20N/M vs Q2 2024 Operating Income-$1,800,778N/M Operating Cash Flowderived-$3,007,151N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Petros Pharmaceuticals, Inc. · CIK 1815903 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end